Filing Details

Accession Number:
0001209191-11-057247
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-11-18 20:01:31
Reporting Period:
2011-11-16
Filing Date:
2011-11-18
Accepted Time:
2011-11-18 20:01:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
858803 Avanir Pharmaceuticals Inc. AVNR Pharmaceutical Preparations (2834) 330314804
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1314596 Keith Katkin 20 Enterprise, Suite 200
Aliso Viejo CA 92656
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-11-16 109,013 $0.53 317,365 No 4 M Direct
Common Stock Disposition 2011-11-16 109,013 $2.59 208,352 No 4 S Direct
Common Stock Acquisiton 2011-11-17 2,587 $0.53 210,939 No 4 M Direct
Common Stock Acquisiton 2011-11-17 106,425 $0.88 317,364 No 4 M Direct
Common Stock Disposition 2011-11-17 109,012 $2.59 208,352 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Disposition 2011-11-16 109,013 $0.00 109,013 $0.53
Common Stock Stock option (right to buy) Disposition 2011-11-17 2,587 $0.00 2,587 $0.53
Common Stock Stock option (right to buy) Disposition 2011-11-17 106,425 $0.00 106,425 $0.88
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
142,087 2018-12-16 No 4 M Direct
139,500 2018-12-16 No 4 M Direct
319,275 2018-07-25 No 4 M Direct
Footnotes
  1. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.56 to $2.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Following the sales reported on this Form 4, the Reporting Person has a total of 862,204 options to purchase shares of common stock that are vested and immediately exercisable and 1,012,412 options to purchase shares of common stock that have not yet vested. Following the sales reported on this Form 4, the Reporting Person also has 62,500 unvested Restricted Stock Units.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.55 to $2.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. The option vested with respect to one-quarter of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares quarterly thereafter over the next three years.
  6. The option vested with respect to 6.25% of the underlying shares upon the achievement of certain performance goals and continues to vest on a quarterly basis over 15 quarters from the initial vesting of the 6.25% upon the achievement of the performance goals.